Summary
Eli Lilly & Company (LLY) filed a Form 8-K on April 18, 2005, to report its financial results for the first quarter ended March 31, 2005. The filing primarily details the company's operational and financial performance, including the issuance of a press release and the holding of a teleconference to discuss these results. A key aspect of the report is the company's use and explanation of non-GAAP financial measures, such as adjusted net income and diluted earnings per share, to provide a clearer year-over-year comparison. These non-GAAP measures exclude significant one-time items from both 2004 and 2005 to offer investors a better view of ongoing operational trends. Notable exclusions include charges for acquired in-process research and development, asset impairments, restructuring costs, and the impact of adopting new accounting standards for share-based payments. The company emphasizes that these adjusted figures are intended to supplement, not replace, GAAP-based reporting and are used internally for performance evaluation. Additionally, the report announces the retirement of a director in compliance with the company's policy.
Key Highlights
- 1The Form 8-K reports Eli Lilly's financial results for the first quarter of 2005.
- 2The company utilizes and explains non-GAAP financial measures (adjusted net income, EPS) for improved year-over-year comparisons.
- 3Key adjustments to 2004 results include charges for acquired in-process R&D and asset impairments.
- 4The adoption of new accounting standards for share-based payments (effective January 1, 2005) is highlighted, with pro-forma adjustments made to 2004 figures for comparability.
- 5The company provides forward-looking financial expectations for Q2 and full-year 2005, including EPS growth on an adjusted basis.
- 6Steven C. Beering, M.D., is retiring from the Board of Directors in accordance with the company's retirement policy.
- 7A press release and related financial statements are attached as Exhibit 99.